Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Global phase III trial of recombinant COVID-19 vaccine (Sf9 cells) in adults
ChiCTR2100046272Phase 3Recruiting
- Sponsor
- Jiangsu Provincial Center for Disease Control and Prevention
- Start
- Jun 2021
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of recombinant COVID-19 (XBB) trimer protein vaccine in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Jiangsu Provincial Center for Disease Control and Prevention. Primary endpoints: Virologically confirmed symptomatic COVID-19 after 3-dose series (>28 days), Serious adverse events through 6 months and 3 more. Started Jun 2021; status: recruiting.
02
Drugs
recombinant COVID-19 (XBB) trimer protein vaccine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2100046272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100046272.